ESMO VIRTUAL ADVANCED COURSE PROGRAMME
KRAS targeting in NSCLC
28-29 November 2022

CO-CHAIRS: Myung-Ju Ahn, Korea
             Federica Di Nicolantonio, Italy

SPEAKERS:   Mariano Barbacid, Spain
            Keith M. Kerr, United Kingdom
            Hye Ryun Kim, Korea
            Se-Hoon Lee, Korea
            Shun Lu, China
            Laura Mezquita, Spain
            Misako Nagasaka, United States
            Takashi Seto, Japan
            Ferdinandos Skoulidis, United States
            Daniel S. W. Tan, Singapore

LEARNING OBJECTIVES

- Understanding the function and biology of KRAS in normal and malignant cells
- Gaining insights in the spectrum of KRAS molecular aberrations, platforms and strategies for molecular testing
- In depth discussion of emerging therapeutic strategies and clinical research in KRAS mutated NSCLC
- Presenting novel data on biomarkers of benefit, mechanisms of resistance and combinatorial therapeutic strategies of KRAS G12C inhibition and beyond

All timings are to be considered GMT+8 (Singapore Local Time)

Monday, 28 November 2022

15:00-15:10 Welcome and introduction
           Myung-Ju Ahn, KR
           Federica Di Nicolantonio, IT

15:10-16:45 Session 1 – KRAS Biology, Epidemiology, Pathology

- 20’ The structure, function and role of KRAS in normal cell homeostasis
      Mariano Barbacid, ES

- 20’ Epidemiology of KRAS activating mutations: Incidence and biology across tumours with emphasis on lung cancer
      Takashi Seto, JP

- 20’ Molecular landscape of KRAS mutant NSCLC (molecular concomitant genetic alterations in KRAS mutant tumours)
      Se-Hoon Lee, KR
20’ Pathology and molecular testing of NSCLC for KRAS mutations: who, how and when? (tissue, liquid biopsy)
Keith M. Kerr, UK

15’ Discussion

16:45-17:00 Break

17:00-18:35 Session 2 – Targeting KRAS G12C in Lung Cancer

20’ Clinical development of KRAS G12C inhibitors – where are we now?
Shun Lu, CN

20’ Resistance to KRAS G12C inhibitors – what do we know?
Daniel S. W. Tan, SG

20’ Moving forward with KRAS G12C inhibitors – combinations (only chemotherapy and targeted therapy sequencing)
Ferdinandos Skoulidis, US

15’ Discussion

20’ Clinical cases and Expert Panel Discussion

10’ with discussion – single agent case with liver toxicity, Shun Lu, CN

10’ with discussion – combination therapy, Ferdinandos Skoulidis, US

Tuesday, 29 November 2022

15:00-16:15 Session 3 – Moving beyond KRAS G12C

20’ Targeting KRAS beyond G12C—what is coming?
Hye Ryun Kim, KR

20’ Targeting KRAS with checkpoint inhibitors
Laura Mezquita, ES

20’ Vaccine and adoptive cell therapy strategies for the treatment of KRAS mutant NSCLC
Misako Nagasaka, US

15’ Discussion

16:15-16:30 Break
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:30-18:00</td>
<td><strong>Workshop Sessions</strong></td>
</tr>
<tr>
<td></td>
<td>10’ Introduction based on clinical cases presented by speakers</td>
</tr>
<tr>
<td></td>
<td>20’ Discussion</td>
</tr>
<tr>
<td>Workshop 1</td>
<td>Liquid biopsy applications for RAS-mutated mutational profiling, monitoring of disease course, clonal evolution and resistance in NSCLC</td>
</tr>
<tr>
<td></td>
<td>30’</td>
</tr>
<tr>
<td></td>
<td>Laura Mezquita, ES</td>
</tr>
<tr>
<td></td>
<td>Keith M. Kerr, UK</td>
</tr>
<tr>
<td>Workshop 2</td>
<td>Moving forward with KRAS G12C inhibitors in early stage/locally advanced NSCLC</td>
</tr>
<tr>
<td></td>
<td>30’</td>
</tr>
<tr>
<td></td>
<td>Shun Lu, CN</td>
</tr>
<tr>
<td></td>
<td>Daniel S. W. Tan, SG</td>
</tr>
<tr>
<td>Workshop 3</td>
<td>Designing practice-changing trials — key considerations</td>
</tr>
<tr>
<td></td>
<td>30’</td>
</tr>
<tr>
<td></td>
<td>Myung-Ju Ahn, KR</td>
</tr>
<tr>
<td></td>
<td>Federica Di Nicolantonio, IT</td>
</tr>
<tr>
<td>18:00-18:15</td>
<td><strong>Synthesis and wrap-up</strong></td>
</tr>
<tr>
<td></td>
<td>Myung-Ju Ahn, KR</td>
</tr>
<tr>
<td></td>
<td>Federica Di Nicolantonio, IT</td>
</tr>
</tbody>
</table>